Related Experiment Videos
Developments in therapy for extensive-disease small cell lung cancer.
1Department of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111.
Seminars in Oncology
|December 1, 1992
Summary
Current treatments for extensive small cell lung cancer offer palliative benefits but not cures. Research is exploring new strategies like resistance modulation and biologic approaches for better survival outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Extensive small cell lung cancer (SCLC) treatment has improved palliative care but not cure rates.
- Chemotherapy dose escalation strategies have yielded mixed results in SCLC patients.
Purpose of the Study:
- To review current treatment strategies for extensive small cell lung cancer.
- To identify areas for future research and improved therapeutic outcomes.
Main Methods:
- Review of existing literature on SCLC chemotherapy regimens.
- Analysis of dose escalation, alternating chemotherapy, and etoposide-based treatments.
Main Results:
- While alternating chemotherapy shows some benefit, significant survival improvements remain elusive.
- Dose escalation strategies have not consistently improved outcomes for extensive SCLC.
Conclusions:
- Current treatment goals for extensive SCLC should prioritize symptom palliation.
- Future research should focus on resistance modulation, biologic therapies, and protracted etoposide treatment to improve survival.